Objective: Sleep disorders in Parkinson's disease are very common. Polysomnography (PSG) is considered the gold standard for diagnosis. The aim of the present study is to assess the prevalence of nocturnal sleep disorders diagnosed by polysomnography and to determine the associated clinical factors. Method: A total of 120 patients with Parkinson's disease were included. All patients underwent a standardized overnight, single night polysomnography. Results: Ninety-four (78.3%) patients had an abnormal PSG. Half of the patients fulfilled criteria for sleep apnea-hypopnea syndrome (SAHS); rapid eye movement behavior disorder (RBD) was present in 37.5%. Characteristics associated with SAHS were age (p = 0.049) and body mass index (p = 0.016). Regarding RBD, age (p , 0.001), left motor onset (p = 0.047) and levodopa equivalent dose (p = 0.002) were the main predictors. Conclusion: SAHS and RBD were the most frequent sleep disorders. Higher levodopa equivalent dose and body mass index appear to be risk factors for RBD and SAHS, respectively.
Parkinson's disease (PD) is a neurological disorder characterized by motor symptoms such as bradykinesia, resting tremor, rigidity, impaired postural reflexes, as well as nonmotor symptoms such as hyposmia, autonomic dysfunction, neuropsychiatric symptoms, pain, and sleep disturbances 1 . Sleep disorders are among the most common non-motor symptoms, with a prevalence of 60% to 90% 2 . Most frequent sleep disorders described in patients with PD are insomnia, excessive daytime sleepiness, rapid eye movement (REM) behavior disorder (RBD), sleep apnea-hypopnea syndrome (SAHS), restless legs syndrome (RLS) and periodic limb movements (PLM) 3 . The sleep disorders may be caused by the nocturnal motor symptoms of PD itself, adverse effects of antiparkinsonian medications or comorbid primary sleep disorders. Sleep disorders can be evaluated by anamnesis, clinical scales and neurophysiological techniques.
Frequently used scales for assessment of sleep disorders include the Parkinson Disease Sleep Scale (PDSS) 4 , Parkinson Disease Sleep Scale -2 (PDSS-2) 5 , Scales for Outcomes in PD-Sleep (SCOPA-Sleep scale) 6 , Epworth Sleepiness Scale (ESS) 7 and the Pittsburgh sleep quality index (PSQI) 8 . Clinical evaluation may be not enough to accurately diagnose sleep disorders. Polysomnography (PSG) is considered the gold standard to diagnose and evaluate the severity of nocturnal sleep disorders 9 . Nocturnal psychosis and nocturia are the only items of PDSS that have been reported to correlate with some PSG parameters in patients with PD 10 .
The main objective of the study is to describe the prevalence of the different sleep disorders in patients with PD evaluated by PSG. 11 . Body mass index (BMI) was calculated with the weight divided by the square of their height; overweight was defined as BMI . 25 kg/m 2 . All patients were examined during the "on" period. Use of antiparkinsonian medication was noted and levodopa equivalent daily dose (LEDD) was calculated 12 . History of current use of other medications were recorded, including antipsychotics, anxiolytics, antidepressants and sleep inducers.
METHOD
All patients underwent a standardized overnight, single night PSG at the Sleep Clinic using a Grass Technologies TWin (version 4.5.0.27) Polysomographer. Conventional electroencephalography electrodes (F4-M1,C4-M1,O2-M1) where placed in most patients with the exception when RBD was clinically suspected and the international 10-20 system for electrode placement was applied in order to rule out Epilepsy. Electrocardiography, chin, upper and lower extremities electromyography (EMG), electro-oculography pulse oximetry, abdominal and chest respiratory effort acquisition were also registered according to the recommended specifications of the American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events. PSG was later scored and analyzed by a sleep medicine specialist. The following parameters were obtained: total sleep time, sleep efficiency, percentage of time spent in non-REM (N) and REM (R) sleep, wake after sleep onset (WASO), sleep latency, R sleep latency, apnea/hypopnea index, minimum and maximum oxygen saturation, minimum and maximum heart rate, cardiac dysrhythmias and periodic limb movement index. History of dream enactment behaviors, PSG recorded dream enactment behaviors and REM sleep without atonia according to the Monplasir method were also noted 13 . SAHS severity was defined as mild for an Apnea-Hypopnea Index (AHI) $ 5 and , 15, moderate for AHI $ 15 and # 30, and severe for AHI . 30/hr 14 . PLM was classified as mild, moderate or severe according to the International Classification of Sleep Disorders 15 . Additionally, the diagnosis of a sleep disorder was made according to the International Classification of Sleep Disorders 2 nd edition when applicable.
Patients with a non-assessable polysomnography were excluded The Spanish version of the SCOPA-Sleep scale was applied to all patients before performing the PSG; the sleep specialist was blinded to the scale score to avoid bias.
The study was approved by the institutional review board and ethics committee. All patients signed a written informed consent.
Statistical analysis
Measures of central tendency and dispersion for descriptive analysis were obtained. Comparison between quantitative variables was performed using a Student's t-test. Qualitative variable were compared using Chi-square test or Fisher's test as needed. Logistic regression models were performed using the presence of the sleep disorders as the dependent variables. Independent variables included in the model were gender, age, disease duration, UPDRS III score, BMI, side of motor onset and LEDD. Statistical significance was set at p , 0.05. SPSS version 17 (SPSS Inc.) was used for all analyses.
RESULTS
One hundred twenty five PD patients were initially included; five of them were excluded due to insufficient sleep time, male gender was more frequent (55.8%). Mean age of the sample was 59.8 ± 13 years. Mean BMI was 27.6 ± 4.5 kg/m 2 , a total of 92 (76.6%) patients had overweight. Mean disease duration was 6.5 ± 6.2 years. A total of 89 (70%) patients had a right sided motor PD onset; motor phenotype was tremor-dominant in 76 (63.3%) patients. The mean UPDRS III score was 28.5 ± 17.
Regarding PD treatment, 92 (73.6%) were on levodopa (mean daily dose 414.6 ± 340.5 mg), 88 (71.6%) were taking a dopamine agonist, 19 (15.8%) were on rasagiline and 12 (10%) were also receiving entacapone. Two patients were not taking any antiparkinsonian medication at the time of the study. The mean levodopa equivalent daily dose was 562.6 ± 376.9 mg. Motor fluctuations were present in 28 (23.3%) patients and dyskinesia was reported in 18 (15%).
The SCOPA-Sleep scale mean score was 10.8 ± 6.6. According to this scale, a total of 49 (40.8%) patients had diurnal sleep problems, while 47 (39.2%) patients had sleep problems at nighttime. The most frequent sleep disorder by clinical diagnosis was insomnia in 103 (82.4%).
Overnight videopolysomnography studies
A total of one hundred twenty PSG were included in the final analysis. Only 26 (21.7%) patients had a normal PSG and 94 (78.3%) an abnormal PSG. Sixty-one (50.8%) of the patients fulfilled criteria for SAHS; mild in 31 (50.8%), moderate in 13 (21.3%) and severe in 17 (27.9%). PLM was diagnosed in 39 patients (32.5%); 23 (58.9%) were classified as mild, 6 (15.4%) as moderate and 10 (25.7%) were severe. RBD was present in 48 (37.5%) diagnosed either by history of dream enactment behavior plus R without atonia or capturing an episode on video-EEG. Additionally R sleep without atonia was noted in seven subjects (5.8%).
Forty nine percent of the patients with a sleep disorder had a dual pathology. The most frequent association was SAHS and RBD in 15.8% of the cases. The prevalence and comorbidity of each sleep disorder are shown in Table 1 .
Sleep efficiency was poor in 33 subjects (27.5%). Other relevant polysomnographic sleep abnormalities were prolonged sleep and R sleep latency as well as diminished slow wave sleep. Total R sleep time was normal. Table 2 shows the mean values for each of the PSG parameters analyzed in the present study.
Clinical correlates of sleep disorders
Comparisons of the main demographic and clinical characteristics between PD patients with and without a PSG sleep disorder is shown in Table 3 . Sleep disorders were more prevalent in males (p = 0.004). Regarding sociodemographic and clinical characteristics among men and women with an abnormal PSG, women showed a trend to be treated more frequently with a dopaminergic agonist (p = 0.05).
Sleep apnea-hypopnea syndrome was more prevalent in males (65% vs 35%, p = 0.03) as well as in overweight patients (p = 0.01). RBD was also more frequent in males (65.3% vs 34.6%, p = 0.048).
In the logistic regression analysis the characteristics associated with SAHS were age (B = 1.033, p = 0. 
DISCUSSION
Sleep disorders are common in PD and they have an impact on the patient's quality of life. Sleep disorders can present as a premotor symptom, as part of the progression of the disease or as a side-effect of the medication used in symptomatic therapy. Moreover, coexisting anxiety and depression can worsen sleep. Motor symptoms like tremor, nocturnal rigidity and hypokinesia can decrease during sleep but do not disappear completely, altering the quality of sleep. Tremor can persist during N sleep causing arousals; rigidity persists mainly in patients with motor fluctuations, and bradykinesia difficult the mobility 16 . The overall prevalence of any sleep disturbances by PSG in our study was 78%, which is similar to the 80% reported in international studies 2, 17 . The most frequent sleep complaint was insomnia, which presented in 82% of our population. The prevalence of the other sleep disorders in our cohort was also comparable to international reports. RBD was identified in 37.5% of our population and was more common in male patients. This is consistent with previous reports, the frequency of RBD in patients with PD assessed by questionnaires or interviews ranges from 15% to 45% but when a PSG is performed the prevalence ranges from 46% to 58% 18, 19, 20 . The factors associated with the presence of RBD in our sample were the LEDD and left side of motor onset of disease. A study comparing patients with or without RBD reported that RBD was associated with older age, longer disease duration, and higher dose of levodopa 21 . Regarding the laterality of motor onset, a recent study reported a trend toward an increased frequency of RBD in PD patients who had a leftsided onset of symptoms 22 , while another study showed an increased frequency of nocturnal hallucinations and daytime dozing in PD patients with a left sided motor onset 23 . This findings suggests a pathophysiological role of the right side brain in the development of RBD in PD patients.
It should be noticed that gender was a significant variable in the bivariate analysis but not after the multivariate regression was performed, thus suggesting the presence of a covariate or effect modifier factor.
SAHS was diagnosed in half of the patients. Reports on the frequency of this disorder ranges from 27% to 60% 3, 24, 25 . Predictors of SAHS in our sample were an older age and higher BMI. The role of BMI as a risk factor for SAHS in PD has been well described 26 . Finally, PLM occurred in 32.5% patients which is also similar to other reports 16 . Risk factors reported in other studies include older age and severity of the disease 27, 28 ; nevertheless none of these factors were associated with the frequency of PLM in our sample.
Polysomnographic sleep parameters disturbances associated with PD are poor sleep efficiency, a decrease in the quantity of N3 sleep, and R sleep 29 . In our patients, total N3 sleep was low but was not considered a clinical significant finding due to the fact that N3 diminishes with age.
SCOPA-Sleep scale did not show an association with PSG diagnoses or parameters in our study. Only PDSS have been reported to correlate with sleep efficiency as measured by PSG 10 ; this finding should warrant the clinician to not rely only in clinical scales to diagnose a sleep disorder in PD patients. PSG should still be considered the gold standard for this purposes.
Our study has limitations. We did not include healthy controls, which makes it difficult to explain if the some sleep disorders result from the patient's age rather than disease or antiparkinsonian therapy. We cannot determine if the variety of the of the sleep disorders is higher in this particular population. A sleep latency test to assess excessive daytime sleepiness was not performed. In conclusion, the most prevalent sleep disorders in patients with PD in our sample was insomnia, followed by SAHS, RBD and PLM. Similarities with other PSG international studies strongly suggest that PSG is reliable and important to correctly diagnose sleep disorders. Higher LEDD and higher BMI appear to be risk factors for RBD and SAHS, respectively. A left sided on motor onset of the disease also appear to be a risk factor for RBD and warrants further study.
